Harmony’s ZYN002 Is Latest Drug To Flunk In Fragile X Syndrome

Harmony announced the failure of the Phase III RECONNECT trial of ZYN002 in fragile X syndrome. • Source: Shutterstock

More from Clinical Trials

More from R&D